2007-06-22T11:31:38
The Medicines and Healthcare products Regulatory Agency is writing to HIV specialists and patient organisations setting out an action plan following the recall of HIV/AIDS drug Viracept (nelfinavir) due to contamination.
With a HSJ subscription you’ll unlock:
Already a subscriber? Sign into your account here
Part of HSJ Information Ltd. The White Chapel Building, 1st Floor, 10 Whitechapel High Street, London, E1 8QS. Registered in England and Wales. Company registration 2530185
Site powered by Webvision Cloud